Navigating Pancreatic Cancer
We are here to empower you to ask bold questions, seek out the best treatment options, and face the unique challenges of pancreatic cancer head-on. We want to give you the resources and information you need to make informed decisions that are best for you.
As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis. Understand your disease. Thoroughly understand what stage of pancreatic cancer you have and inquire about having your blood and tumor genetically sequenced. […]
If you have been diagnosed with pancreatic cancer, a clinical trial may be your best treatment option. Many clinical trials are underway for patients in all stages of the disease and may involve new combinations of currently available drugs or new drugs that have worked in other cancers. No matter where you are in your journey, we encourage you to learn more about clinical trials.
LET’S WIN! Pancreatic Cancer A Dynamic Way to Share Information Recognizing that there is an urgent need for patients to communicate amongst themselves and with the medical community about potentially life-changing treatments and clinical trials, we are proud to be affiliated with Let’s Win. Let’s Win is an interactive online community where patients and families […]
Pancreatic Cancer Connections is online social community that provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Patients interact with others who are facing a pancreatic cancer and can post questions to the board or message other members privately. This community forum is a valuable resource for patients, caregivers, and their loved ones to refer to at various stages of their treatment and recovery.
Patients and loved ones can sign up for Pancreatic Cancer Connections at no cost and will be welcomed into an engaging and supportive community to discuss topics including treatment options, nutrition, and coping with the disease. Pancreatic Cancer Connections is hosted by Inspire, a leading healthcare social network that connects more than 1,000,000 patients and caregivers.
View All Articles
Holiday Rock & Roll Bash 2018
It’s a night of holiday fun – dancing, delicious food and drinks, and an exclusive performance by the world-famous Radio City Rockettes. We gather to celebrate our success while remembering there is still much more work to be done.
Information on purchasing tickets or, sponsorships and making a donation is below.
Largest Match Ever #FundMoreTrials
Meet Vivian — a Stage IV pancreatic cancer patient with liver metastases who is alive today thanks to an immunotherapy clinical trial that was built upon research done through the Lustgarten Foundation and Stand Up To Cancer. She is now on a maintenance regimen to prevent a recurrence and is grateful for every day she gets to spend with her family and friends.
Stories like Vivian’s demonstrate why it is so critical that we fund as much research and as many clinical trials as possible and give other patients the chance for long-term survival. One promising multicenter trial we need to fund is PASS (Pancreatic Adenocarcinoma Signature Stratification), and we need your support. The goal is to identify medications that work best for first and second-line treatment by testing different therapies, as patients with advanced disease don’t have time to waste.
We need to ensure that as many patients as possible have the opportunity to participate in clinical trials that offer alternatives to standard of care treatments, test new therapy combinations and challenge conventional methods for treating a disease with the lowest five-year survival rate of any major cancer.
By supporting the Lustgarten Foundation, you are accelerating clinical trials that are leading to life-changing breakthroughs in pancreatic cancer treatment.
Request For Applications
Seeking Computational Approaches to Identifying High Risk Populations
The Pancreatic Cancer Collective is seeking proposals utilizing artificial intelligence (AI) to identify high risk pancreatic cancer populations. We are funding two projects — each to support a different approach to identifying individuals in the general population who are at high risk for pancreatic cancer much earlier than they would otherwise be diagnosed:
- High Risk Cohorts Through Real World Data: We invite submission of ideas develop a tool to prospectively identify high-risk populations for pancreatic cancer. The tool should rely on real-world data commonly collected in the community setting and must be broadly generalizable. The award will support model development and additional funding may be made available for validation of a successful model. Initial validation of the tool may be done internally and/or with other databases.
- High Risk Cohorts Through Molecular and Genetic Data: We invite submission of ideas for a project that would explore the use of deep genetic characterization of germline DNA in conjunction with phenotypic data to markedly increase the prospective identification of high-risk populations for pancreatic cancer.
Both projects should use information from existing dataset such as the OptumLabs Data Warehouse, UK Biobank, Danish National Patient Registry*, and/or other comparable datasets.
The chosen Team(s) will also be encouraged to work closely with one another and/or with existing Teams supported by Stand Up To Cancer and/or the Lustgarten Foundation. Applications will be reviewed by a Joint Scientific Advisory Committee selected by the Collective. Teams with the most promising idea submissions will be invited to attend an in-person selection meeting on January 30, 2019 in Los Angeles. The selected Teams will be awarded up to $1 million over a two-year term of the award, with second year contingent on progress in year one.
Pancreatic Cancer News
View All Articles
McGill, Yale and Universities of Pennsylvania and Massachusetts Join PanFAM-1, the Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer
New centers give study near complete coverage of North American FPC sites in drive to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer — Immunovia AB today announced that four additional North American Familial Pancreatic Cancer (FPC) sites are to participate in PanFAM-1, the largest ever prospective study looking […]
Cancer cells are often described as cells “gone bad” or “renegade.” New research reveals that in some of the deadliest cases of pancreatic cancer, these rebellious cells have an unexpected addiction. Now, scientists are investigating if that addiction can be used to bring about a tumor’s end. Cold Spring Harbor Laboratory (CSHL) research recently published […]
Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields
-Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial have been published in Pancreatology. The PANOVA pilot trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields in patients with advanced pancreatic cancer whose tumors could not be removed surgically and who had not received chemotherapy or radiation therapy prior to entering the clinical trial.
Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced results from a retrospective, observational analysis examining the real-world dosing patterns of patients with metastatic pancreatic cancer (mPC) treated with ONIVYDE® (irinotecan liposome injection), at this year’s European Society for Medical Oncology (ESMO) annual congress taking place in Munich, Germany, Oct. 19-23, 2018.
BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma (PDAC) treated with BL-8040 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside of the United States and Canada).
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.
PDAC is the fourth leading cause of cancer-related deaths, with less than 20% of patients having resectable tumors. While CAR T-cell treatments have shown substantial efficacy in hematological malignancies, outcomes in solid tumors such as pancreatic cancer have been limited.
A new approach to treating pancreatic cancer using ‘educated killer cells’ has shown promise, according to early research by Queen Mary University of London.
The new cell-based immunotherapy, which has not yet been tested in humans with pancreatic cancer, led to mice being completely cancer-free, including cancer cells that had already spread to the liver and lungs.
CDK1 is a “normal” protein – its presence drives cells through the cycle of replication. And MHC Class I molecules are “normal” as well – they present bits of proteins on the surfaces of cells for examination by the immune system. But a University of Colorado Cancer Center study published in the journal Cancer Research shows that a population of cancer cells marked by MHC Class I molecules and high CDK1 is anything but normal.
Cancers are comprised of heterogeneous subpopulations with various tumor-initiating capacities, yet key stem cell genes associated with enhanced tumor initiating capacities and their regulatory mechanisms remain elusive. Here we analyzed patient-derived xenografts from melanoma, colon, and pancreatic cancer tissues and identified enrichment of tumor-initiating cells in MHC class I-hi cells, where CDK1, a master regulator of the cell cycle, was upregulated.
A new treatment that kills two genes responsible for causing pancreatic cancer — one of the most fatal forms of the disease — is being hailed as a possible breakthrough.
Dr. James Cleary, an oncologist at the Dana-Farber Cancer Institute in Boston, said pancreatic cancer research had been “left behind” — but not anymore.